Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans

I. Raz; M. Bialer; K. Salame; H. Bar-On

doi:10.1007/BF00548775

Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans

I. Raz
, M. Bialer^*
, K. Salame
, H. Bar-On

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The pharmacokinetics and relative bioavailability of theophylline from a new sustained-release formulation (Theotard^®) and from a standard sustained-release formulation (Theo-Dur^®) were compared in 6 healthy, adult, male volunteers. After a single oral dose of 300 mg Theotard, a mean maximal plasma concentration (Cb_max of 3.49±1.05 mg/l was obtained after 8 h (t_max). After an identical dose of Theo-Dur, a peak plasma concentration of 4.68±1.33 mg/l was obtained after 6.33 h. The mean relative bioavailability of theophylline from Theotard was 1.02±0.16 relative to that of Theo-Dur. In 5 of the volunteers the Theotard formulation exhibited a more prolonged and uniform absorption rate and yielded more sustained plasma levels.

Original language	English
Pages (from-to)	401-403
Number of pages	3
Journal	European Journal of Clinical Pharmacology
Volume	26
Issue number	3
DOIs	https://doi.org/10.1007/BF00548775
State	Published - May 1984

Keywords

serum concentration
sustained-release dosage form
theophylline

Access to Document

10.1007/BF00548775

Cite this

@article{1c7c4c9df2c6404ca55fdf2a61392b34,

title = "Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans",

abstract = "The pharmacokinetics and relative bioavailability of theophylline from a new sustained-release formulation (Theotard{\textregistered}) and from a standard sustained-release formulation (Theo-Dur{\textregistered}) were compared in 6 healthy, adult, male volunteers. After a single oral dose of 300 mg Theotard, a mean maximal plasma concentration (Cbmax of 3.49±1.05 mg/l was obtained after 8 h (tmax). After an identical dose of Theo-Dur, a peak plasma concentration of 4.68±1.33 mg/l was obtained after 6.33 h. The mean relative bioavailability of theophylline from Theotard was 1.02±0.16 relative to that of Theo-Dur. In 5 of the volunteers the Theotard formulation exhibited a more prolonged and uniform absorption rate and yielded more sustained plasma levels.",

keywords = "serum concentration, sustained-release dosage form, theophylline",

author = "I. Raz and M. Bialer and K. Salame and H. Bar-On",

year = "1984",

month = may,

doi = "10.1007/BF00548775",

language = "אנגלית",

volume = "26",

pages = "401--403",

journal = "European Journal of Clinical Pharmacology",

issn = "0031-6970",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans

AU - Raz, I.

AU - Bialer, M.

AU - Salame, K.

AU - Bar-On, H.

PY - 1984/5

Y1 - 1984/5

N2 - The pharmacokinetics and relative bioavailability of theophylline from a new sustained-release formulation (Theotard®) and from a standard sustained-release formulation (Theo-Dur®) were compared in 6 healthy, adult, male volunteers. After a single oral dose of 300 mg Theotard, a mean maximal plasma concentration (Cbmax of 3.49±1.05 mg/l was obtained after 8 h (tmax). After an identical dose of Theo-Dur, a peak plasma concentration of 4.68±1.33 mg/l was obtained after 6.33 h. The mean relative bioavailability of theophylline from Theotard was 1.02±0.16 relative to that of Theo-Dur. In 5 of the volunteers the Theotard formulation exhibited a more prolonged and uniform absorption rate and yielded more sustained plasma levels.

AB - The pharmacokinetics and relative bioavailability of theophylline from a new sustained-release formulation (Theotard®) and from a standard sustained-release formulation (Theo-Dur®) were compared in 6 healthy, adult, male volunteers. After a single oral dose of 300 mg Theotard, a mean maximal plasma concentration (Cbmax of 3.49±1.05 mg/l was obtained after 8 h (tmax). After an identical dose of Theo-Dur, a peak plasma concentration of 4.68±1.33 mg/l was obtained after 6.33 h. The mean relative bioavailability of theophylline from Theotard was 1.02±0.16 relative to that of Theo-Dur. In 5 of the volunteers the Theotard formulation exhibited a more prolonged and uniform absorption rate and yielded more sustained plasma levels.

KW - serum concentration

KW - sustained-release dosage form

KW - theophylline

UR - https://www.scopus.com/pages/publications/0021356144

U2 - 10.1007/BF00548775

DO - 10.1007/BF00548775

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 6734702

AN - SCOPUS:0021356144

SN - 0031-6970

VL - 26

SP - 401

EP - 403

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

IS - 3

ER -

Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this